Skip to main navigation Skip to search Skip to main content

Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study

  • coopERA Breast Cancer study group
  • University of California at Los Angeles
  • Fred Hutchinson Cancer Research Center
  • Harvard University
  • San Sebastián de los Reyes
  • Institute Catala Oncologia
  • Hospital Universitario San Cecilio
  • University of Granada
  • Hospital Virgen de la Arrixaca
  • NSHI Road Clinical Hospital of JSC Russian Railways
  • Communal Enterprise Kryvyi Rih Oncology Dispensary
  • Hospital do Câncer de Pernambuco
  • Sarah Cannon Research Institute
  • Communal Non-profit Enterprise Odesa Regional Clinical Hospital of Odesa Regional Council
  • Hospital Universitario La Paz
  • Torrance Memorial Hunt Cancer Center
  • Translational Research in Oncology
  • F Hoffmann-La Roche
  • Roche Products Limited UK
  • F. Hoffmann-La Roche AG
  • Genentech, Inc
  • Friedrich-Alexander University Erlangen-Nürnberg

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study'. Together they form a unique fingerprint.
Sort by

Biochemistry, Genetics and Molecular Biology

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry